Q1 EPS Forecast for Sage Therapeutics Boosted by Analyst

Sage Therapeutics, Inc. (NASDAQ:SAGE) – HC Wainwright lifted their Q1 2025 earnings per share estimates for shares of Sage Therapeutics in a report issued on Wednesday, February 12th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will post earnings per share of ($1.11) for the quarter, up from their previous forecast of ($1.54). HC Wainwright has a “Neutral” rating and a $12.00 price objective on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.46) per share. HC Wainwright also issued estimates for Sage Therapeutics’ Q2 2025 earnings at ($1.05) EPS, Q3 2025 earnings at ($1.00) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($4.14) EPS, FY2026 earnings at ($3.56) EPS, FY2027 earnings at ($2.86) EPS, FY2028 earnings at ($2.63) EPS and FY2029 earnings at ($1.84) EPS.

A number of other equities analysts also recently commented on the stock. Piper Sandler reduced their price objective on shares of Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, January 2nd. Stifel Nicolaus reduced their price target on Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating for the company in a research report on Monday, December 16th. TD Cowen dropped their price objective on Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating on the stock in a research report on Thursday, November 21st. Oppenheimer reduced their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Wednesday, October 30th. Finally, StockNews.com cut shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $9.65.

Sage Therapeutics Stock Performance

NASDAQ:SAGE opened at $7.18 on Monday. The firm has a 50-day simple moving average of $6.43 and a 200-day simple moving average of $6.83. Sage Therapeutics has a one year low of $4.62 and a one year high of $23.22. The firm has a market cap of $439.20 million, a P/E ratio of -1.29 and a beta of 0.94.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%.

Institutional Investors Weigh In On Sage Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Picton Mahoney Asset Management raised its position in Sage Therapeutics by 126.0% during the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 3,581 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Sage Therapeutics during the fourth quarter worth $49,000. Ieq Capital LLC acquired a new position in Sage Therapeutics during the fourth quarter valued at $57,000. US Bancorp DE boosted its holdings in Sage Therapeutics by 22.3% in the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 2,268 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its position in Sage Therapeutics by 21.6% during the 4th quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company’s stock worth $75,000 after purchasing an additional 2,446 shares during the period. Institutional investors and hedge funds own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.